• 1
    Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998;102(Pt 1):558562.
  • 2
    Becker WM, Vogel L, Vieths S. Standardization of allergen extracts for immunotherapy: where do we stand? Curr Opin Allergy Clin Immunol 2006;6:470475.
  • 3
    Larenas-Linnemann D, Cox LS. European allergen extract units and potency: review of available information. Ann Allergy Asthma Immunol 2008;100:137145.
  • 4
    Larsen JN, Houghton CG, Vega ML, Lowenstein H. Manufacturing and standardizing allergen extracts in Europe. Clin Allergy Immunol 2008;21:283301.
  • 5
    Sander I, Fleischer C, Meurer U, Bruning T, Raulf-Heimsoth M. Allergen content of grass pollen preparations for skin prick testing and sublingual immunotherapy. Allergy 2009;64:14861492.
  • 6
    van Ree R, Chapman MD, Ferreira F, Vieths S, Bryan D, Cromwell O et al. The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy 2008;63:310326.
  • 7
    van Ree R. The CREATE project: EU support for the improvement of allergen standardization in Europe. Allergy 2004;59:571574.
  • 8
    Committee for Medicinal Products for Human Use (CHMP) and Efficacy Working Party (EWP): Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases; EMEA/CHMP/EWP/18504/2006. 2008.
  • 9
    Arntzen FC, Wilhelmsen TW, Lowenstein H, Gjesing B, Maasch HJ, Stromberg R et al. The international collaborative study on the first international standard of birch (Betula verrucosa)-pollen extract. J Allergy Clin Immunol 1989;83:6682.
  • 10
    Ford A, Seagroatt V, Platts-Mills TA, Lowenstein H. A collaborative study on the first international standard of Dermatophagoides pteronyssinus (house dust mite) extract. J Allergy Clin Immunol 1985;75:676686.
  • 11
    Larsen JN, Ford A, Gjesing B, Levy D, Petrunov B, Silvestri L et al. The collaborative study of the international standard of dog, Canis domesticus, hair/dander extract. J Allergy Clin Immunol 1988;1:318330.
  • 12
    Helm RM, Gauerke MB, Baer H, Lowenstein H, Ford A, Levy DA et al. Production and testing of an international reference standard of short ragweed pollen extract. J Allergy Clin Immunol 1984;73:790800.
  • 13
    Gjesing B, Jager L, Marsh DG, Lowenstein H. The international collaborative study establishing the first international standard for timothy (Phleum pratense) grass pollen allergenic extract. J Allergy Clin Immunol 1985;75:258267.
  • 14
    Brozek JL, Akl EA, Alonso-Coello P, Lang D, Jaeschke R, Williams JW et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy 2009;64:669677.
  • 15
    Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998;51:12351241.
  • 16
    Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996;276:637639.
  • 17
    Golden DB, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Dose dependence of Hymenoptera venom immunotherapy. J Allergy Clin Immunol 1981;67:370374.
  • 18
    Olaguibel JM, Tabar AI, Garcia Figueroa BE, Cortes C. Immunotherapy with standardized extract of Dermatophagoides pteronyssinus in bronchial asthma: a dose-titration study. Allergy 1997;52:168178.
  • 19
    Rueff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001;108:10271032.
  • 20
    Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993;91:709722.
  • 21
    Creticos PS, Marsh DG, Proud D, Kagey-Sobotka A, Adkinson NF Jr, Friedhoff L et al. Responses to ragweed-pollen nasal challenge before and after immunotherapy. J Allergy Clin Immunol 1989;84:197205.
  • 22
    Franklin W, Lowell FC. Comparison of two dosages of ragweed extract in the treatment of pollenosis. JAMA 1967;201:915917.
  • 23
    Didier A, Malling HJ, Worm M, Horak F, Jager S, Montagut A et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:13381345.
  • 24
    Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:802809.
  • 25
    Ewbank PA, Murray J, Sanders K, Curran-Everett D, Dreskin S, Nelson HS. A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract. J Allergy Clin Immunol 2003;111:155161.
  • 26
    Frew AJ, Powell RJ, Corrigan CJ, Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:319325.
  • 27
    Johnstone DE, Crump L. Value of hyposensitization therapy for perennial bronchial asthma in children. Pediatrics 1961;27:3944.
  • 28
    Lent AM, Harbeck R, Strand M, Sills M, Schmidt K, Efaw B et al. Immunologic response to administration of standardized dog allergen extract at differing doses. J Allergy Clin Immunol 2006;118:12491256.
  • 29
    Nanda A, O’Connor M, Anand M, Dreskin SC, Zhang L, Hines B et al. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol 2004;114:13391344.
  • 30
    Skoner D, Gentile D, Bush R, Fasano MB, McLaughlin A, Esch RE. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. J Allergy Clin Immunol 2010;125:660666.
  • 31
    Valovirta E, Jacobsen L, Ljorring C, Koivikko A, Savolainen J. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy 2006;61:11771183.
  • 32
    Didier A, Melac M, Montagut A, Lheritier-Barrand M, Tabar A, Worm M. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy. Allergy 2009;64:166171.
  • 33
    Nieminen K, Valovirta E, Savolainen J. Clinical outcome and IL-17, IL-23, IL-27 and FOXP3 expression in peripheral blood mononuclear cells of pollen-allergic children during sublingual immunotherapy. Pediatr Allergy Immunol 2010;21:e174184.
  • 34
    Savolainen J, Jacobsen L, Valovirta E. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy 2006;61:11841190.
  • 35
    Savolainen J, Nieminen K, Laaksonen K, Laiho T, Jacobsen L, Lahesmaa R et al. Allergen-induced in vitro expression of IL-18, SLAM and GATA-3 mRNA in PBMC during sublingual immunotherapy. Allergy 2007;62:949953.
  • 36
    Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacother 2010;1:100107.
  • 37
    Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007;62:317324.
  • 38
    Thomas N. Hypothesis testing and Bayesian estimation using a sigmoid Emax model applied to sparse dose-response designs. J Biopharm Stat 2006;16:657677.
  • 39
    Chapman MD, Ferreira F, Villalba M, Cromwell O, Bryan D, Becker WM et al. The European Union CREATE project: a model for international standardization of allergy diagnostics and vaccines. J Allergy Clin Immunol 2008;122:882889.
  • 40
    Barber D, Serrano C, Jimeno L. Pharmacokinetics of an allergen adsorbed to aluminium. Presented at the 29th Congress of the European Academy of Allergy and Clinical Immunology, London, 2010.
  • 41
    Jimeno L, Serrano C, Barber D. Adjuvant influence on pharmacokinetics of allergen vaccine. Presented at the 29th Congress of the European Academy of Allergy and Clinical Immunology, London, 2010.
  • 42
    Rask C, Lund L, Lund G, Urioste S, Thorup S, Bergmann K et al. Optimised allergen: adjuvant ratio potentiates immunogenicity of AlOH-formulated Phleum pratense extract. Presented at the 29th Congress of the European Academy of Allergy and Clinical Immunology, London, 2010.
  • 43
    Jung K, Wolf H, Schnitker J, Wüstenberg E. Subcutaneous immunotherapy with a preparation with optimised allergen aluminium hydroxide ratio: a randomised parallel-group clinical trial investigating safety and tolerability. Presented at the 29th Congress of the European Academy of Allergy and Clinical Immunology, London, 2010.
  • 44
    Wolf H, Jung K, Schnitker J, Wustenberg E. Subcutaneous immunotherapy with a preparation with optimised allergen aluminium hydroxide ratio: immunologic effects. Presented at the 29th Congress of the European Academy of Allergy and Clinical Immunology, London, 2010.
  • 45
    Rask C, Brimnes J, Lund K. Shorter dosing intervals of sublingual immunotherapy lead to more efficacious treatment in a mouse model of allergic inflammation. Scand J Immunol 2010;71:403412.
  • 46
    Francis JN. The facilitated antigen binding (FAB) assay – a protocol to measure allergen-specific inhibitory antibody activity. Methods Mol Med 2008;138:255261.
  • 47
    Shamji MH, Wilcock LK, Wachholz PA, Dearman RJ, Kimber I, Wurtzen PA et al. The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods 2006;317:7179.
  • 48
    Kleine-Tebbe J. Specific immunotherapy by different allergen applications: subcutaneous, sublingual, oral or rectal administration and lymph node injection. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 2009;96:8795.
  • 49
    Bagnasco M, Passalacqua G, Villa G, Augeri C, Flamigni G, Borini E et al. Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin Exp Allergy 2001;31:5460.
  • 50
    Kleine-Tebbe J, Ribel M, Herold DA. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy 2006;61:181184.
  • 51
    Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: the World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol 2010;125:569574.
  • 52
    Committee for Proprietary Medicinal Products (CPMP) and Biotechnology Working Party (BWP): Guideline on allergen products. Production and quality issues; CPMP/EMEA/BWP/304831/2007. 2008.
  • 53
    EMA/PDCO. Standard paediatric investigation plan for allergen products for specific immunotherapy: revision 2. 2010; EMA/PDCO/737605/2009.
  • 54
    Godicke V, Hundt F. Registration trials for specific immunotherapy in Europe: advanced guidance from the new European Medical Agency guideline. Allergy 2010;65:14991505.
  • 55
    Ventas P, Lombardero M, Duffort O, Carreira J. Cuantificacion de los alergenos Der p l y Der/1 de los acaros y Fel rf I de gato mediante un ELISA en fase solida. Rev Esp Alergol Inmunol Chn 1990;5:715.
  • 56
    Larenas-Linnemann D, Cox LS. European allergen extract units and potency: review of available information. Ann Allergy Asthma Immunol 2008;100:13745.
  • 57
    Hrabina M, Jain K, Gouyon B. Cross-reactivity between pollen allergens from common Pooideae grasses and cultivated cereals. Clin Exp Allergy Rev 2008;1:1820.